The Outbreak of COVID-19 Has Increased Demand for India Mucormycosis Treatment (Black Fungus Drugs)

India Mucormycosis Treatment (Black Fungus Drugs)
India Mucormycosis Treatment (Black Fungus Drugs)

India Mucormycosis Treatment (Black Fungus Drugs) involves prescription antifungal medicine, such as isavuconazole, posaconazole, or amphotericin B. Isavuconazole and posaconazole can also be administered orally, while isavuconazole, posaconazole, and amphotericin B are given intravenously. Mucormycosis, also known as black fungus, is a fungal infection caused by a group of microorganisms belonging to the phylum Glomeromycota. It is an aggressive, life-threatening infection requiring prompt diagnosis and early treatment.

Black Fungus, scientifically known as Mucormycosis, is an aggressive, severe and rare fungal infection that is affecting a number of pre and post COVID-19 patients. It's caused by a group of molds called mucormycetes and often affects the sinuses, lungs, skin, and brain. India has reported a recent surge in mucormycosis cases. According to the World Health Organization (WHO), in India, prevalence of mucormycosis is estimated as 140 per million population, which is about 80 times higher than the prevalence in developed countries.

With the increasing COVID-19 cases across the globe, the Demand For India Mucormycosis Treatment (Black Fungus Drugs) Market. In June 2021, Mexico reported the country's first case of mucormycosis (black fungus) in recovering COVID-19 patient. COVID-19 does not necessarily increase the risk of mucormycosis, but excessive use of steroids for treatment may be the cause that patients with COVID-19 have this infection. Thus, there is an increasing demand for mucormycosis treatment (black fungus drugs) worldwide, especially in India.

In June 2021, Mankind Pharma launched Posaconazole Gastro resistant tablets, used for the treatment of black fungus. Moreover, in May 2021, Bajaj Healthcare launched Posaconazole API, to treat India Mucormycosis Treatment (Black Fungus Drugs) infection in the COVID-19 patients. Mucormycosis treatment consists of antifungal drugs and surgery. Successful management of mucormycosis requires early diagnosis, reversal of underlying predisposing risk factors, surgical debridement and prompt administration of active antifungal agents. However, mucormycosis is not always amenable to the treatment.

Source Link: https://www.globenewswire.com/news-release/2021/05/31/2238830/0/en/India-Mucormycosis-Treatment-Black-Fungus-Drug-Market-to-Surpass-US-11-7-Million-by-2028-Says-Coherent-Market-Insights-CMI.html

Comments

Popular posts from this blog

Structure and Operation Principle of the Neuronavigation System: Applications and Trends

Innovation Unleashed: Exploring Valves' Limitless Possibilities

Creating a Connected Healthcare Ecosystem: Healthcare IT Consulting Strategies